SL-325 for Crohn's Disease
(RECEPTIVE-CD1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease.
The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.
Are You a Good Fit for This Trial?
This trial is for adults with moderate to severe Crohn's disease who have not responded well, stopped responding, or couldn't tolerate previous standard treatments. Participants must have had their diagnosis confirmed at least 3 months ago and meet certain disease activity scores.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- SL-325
Trial Overview
The study compares a new drug called SL-325 to a placebo in people with active Crohn's disease. Participants are randomly assigned to receive either SL-325 or an inactive treatment over several phases lasting up to about one year.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shattuck Labs, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.